Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

March 3, 2020

Study Completion Date

June 10, 2020

Conditions
Renal Cell CarcinomaMetastatic Renal Cell CarcinomaNon-metastatic Renal Cell Carcinoma
Interventions
DRUG

Axitinib Oral Tablet

"Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities and blood pressure.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day with or without food as per instruction. On clinic days only, patients will be advised to fast for 6 hours prior to their clinic visit.~Patients should be advised to stop axitinib treatment a minimum of 36 hours and maximum of 7 days prior to week 9 nephrectomy and thrombectomy surgery.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."

Trial Locations (7)

CM1 7ET

Broomfield Hospital, Chelmsford

CB2 0QQ

Addenbrookes Hospital, Cambridge

EH4 2XU

Western General Hospital, Edinburgh

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

NW3 2QG

Royal Free Hospital, London

SW17 0QT

St George's Hospital, London

SW3 6JJ

Royal Marsden, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Scottish Clinical Trials Research Unit

OTHER

NCT03494816 - Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion | Biotech Hunter | Biotech Hunter